Technical Analysis for SPPI - Spectrum Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade A 21.32 -1.43% -0.31
SPPI closed down 1.43 percent on Friday, February 16, 2018, on 40 percent of normal volume.
4 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical SPPI trend table...

Date Alert Name Type % Chg
Feb 16 Inside Day Range Contraction 0.00%
Feb 16 Wide Bands Range Expansion 0.00%
Feb 15 Spinning Top Other -1.43%
Feb 15 Wide Bands Range Expansion -1.43%
Feb 14 Multiple of Ten Bullish Other 0.19%
Feb 14 Wide Bands Range Expansion 0.19%
Feb 13 NR7 Range Contraction 4.72%
Feb 13 Multiple of Ten Bullish Other 4.72%
Feb 13 Inside Day Range Contraction 4.72%
Feb 13 Wide Bands Range Expansion 4.72%

Older signals for SPPI ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.
Is SPPI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 23.5
52 Week Low 5.47
Average Volume 1,125,331
200-Day Moving Average 13.2118
50-Day Moving Average 19.7092
20-Day Moving Average 21.27
10-Day Moving Average 20.722
Average True Range 1.1621
ADX 16.46
+DI 24.4
-DI 17.58
Chandelier Exit (Long, 3 ATRs ) 20.0137
Chandelier Exit (Short, 3 ATRs ) 22.0363
Upper Bollinger Band 22.9637
Lower Bollinger Band 19.5763
Percent B (%b) 0.51
BandWidth 15.925717
MACD Line 0.3307
MACD Signal Line 0.3841
MACD Histogram -0.0534
Fundamentals Value
Market Cap 1.68 Billion
Num Shares 78.8 Million
EPS -1.00
Price-to-Earnings (P/E) Ratio -21.32
Price-to-Sales 11.56
Price-to-Book 7.68
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 22.52
Resistance 3 (R3) 22.51 22.11 22.32
Resistance 2 (R2) 22.11 21.80 22.11 22.25
Resistance 1 (R1) 21.71 21.61 21.51 21.72 22.19
Pivot Point 21.31 21.31 21.21 21.31 21.31
Support 1 (S1) 20.91 21.00 20.71 20.92 20.45
Support 2 (S2) 20.51 20.81 20.51 20.39
Support 3 (S3) 20.11 20.51 20.32
Support 4 (S4) 20.12